Swipe for more

• October 22, 2026

  bioMérieux receives Dual 510(k) Clearance and CLIA Waiver from the FDA for the BIOFIRE® SPOTFIRE® Vaginitis Panel to Advance Women’s Health with Rapid Molecular Diagnostics

  bioMérieux's BIOFIRE® SPOTFIRE® Vaginitis (VG) Panel has received Dual 510(k) Clearance and CLIA Waiver* from the U.S. Food and Drug Administration (FDA).

  Read more
  

• October 19, 2026

  WHO Grants Emergency Use Listing for BIOFIRE® Global Fever Special Pathogens Panel, Expanding Access to Differential Diagnostics for the Ebola Response

  bioMérieux, a world leader in in vitro diagnostics, announced that the World Health Organization (WHO) has granted Emergency Use Listing (EUL) for the BIOFIRE® Global Fever Special Pathogens Panel, strengthening access to differential diagnostic testing in support of the ongoing Ebola Bundibugyo outbreak affecting the Democratic Republic of the Congo (DRC) and neighboring countries.

  Read more
  

• September 24, 2026

  bioMérieux Launches SPINCHIP^® hs-cTnl, a Major Innovation for the Measurement of High-Sensitivity Cardiac Troponin I and Faster Management of Cardiac Emergencies

  Marcy-l’Étoile (France), September 24, 2026 – bioMérieux, a global leader in in vitro diagnostics, today announced the launch of SPINCHIP®, an innovative point-of-care platform, featuring its first test for the measurement of high-sensitivity cardiac troponin I from a single drop of blood: SPINCHIP® hs-cTnl. Presented at the European Society of Emergency Medicine (EUSEM) Congress in Paris, this rapid diagnostic solution will initially be available in Europe, bringing a critical test closer to the point of care and helping emergency teams quickly triage adult patients with suspected acute myocardial infarction.

  Read more